^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cdactin-O (CBM588)

    i
    Associations
    News

    Trials

    Company:
    Miyarisan, Osel
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (NCT03922035)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/22/2024
    Initiation :
    04/18/2019
    Primary completion :
    12/24/2024
    Completion :
    12/24/2024
    TNFA • TNFRSF1A • TGFB1
    |
    Cdactin-O (CBM588)
    CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (P30CA033572) (NCT03829111)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/01/2024
    Initiation :
    05/14/2019
    Primary completion :
    06/11/2024
    Completion :
    06/11/2024
    IL6 • CXCL8
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cdactin-O (CBM588)